Posted Mar. 11, 2013 at 6:51 a.m.

Premium Lock GSK diabetes drug could deliver big dividend for Novozymes

Published: 2013-03-11 06:51:03
Updated: 2013-03-11 06:51:03

Print this blog post
Novozymes' facility in Franklinton  Novozyme's facility in Franklinton Image 1 of 2 · Next Image…

Novozymes technology promises to increase the active life of the new diabetes drug, meaning type 2 diabetes sufferers could inject once a week instead of daily. Novozymes uses genetically modified proteins that allow GSK to fuse its drug with albumin found in blood serum, fooling the body into accepting the active ingredients that it would normally deem foreign and expel....

Read More
Read More

WRAL Tech Wire any time: Twitter, Facebook

Copyright 2014 WRAL Tech Wire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Scroll